Senescence represents a state of indefinite growth arrest in cells that have reached the end of their replicative life span, have become damaged, or express aberrant levels of cancer-related proteins. While senescence is widely considered to represent a tumor-suppressive mechanism, the accumulation of senescent cells in tissues of older organisms is believed to underlie age-associated losses in physiologic function and age-related diseases. With the emergence of microRNAs (miRNAs) as a major class of molecular regulators of senescence, we review the transcriptional and post-transcriptional factors that control senescence-associated microRNA biosynthesis. Focusing on their enhancement or repression of senescence, we describe the transcription factors that govern the synthesis of primary (pri-)miRNAs, the proteins that control the nuclear processing of pri-miRNAs into precursor (pre-)miRNAs, including RNA editing enzymes, RNases, and RNA helicases, and the cytoplasmic proteins that affect the final processing of pre-miRNAs into mature miRNAs. We discuss how miRNA biogenesis proteins promote or inhibit senescence, and thus influence the senescent phenotype that affects normal tissue function and pathology.
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Introduction
As first described by Hayflick almost 50 years ago (Hayflick, 1965) , most untransformed cells divide in culture for a finite number of times, after which they reach a state of long-term, G1-phase growth arrest named senescence. Although senescent cells do not divide, they can remain viable and metabolically active for a long time, displaying a senescence-associated secretory phenotype (SASP) (Coppé et al., 2010) . Cellular senescence is triggered by many factors, including DNA damage caused by telomere erosion (the loss of chromosome ends as they shorten progressively with each round of division), oxidative damage, and excessive mitogenic signals from activated oncoproteins or inactivated tumor suppressors (Kuilman et al., 2010 
In vivo senescence
Senescence is widely recognized as a tumor suppressor mechanism, as evidenced by several facts: (i) some factors that promote tumor growth can also trigger senescence, and thus senescence is viewed as a safeguard mechanism against tumorigenesis following oncogenic stimulation, (ii) that senescence depends on two major tumor suppressor pathways (p53 and pRB/p16), and (iii) that defects in these pathways fail to trigger senescence and lead to tumorigenesis (Narita and Lowe, 2005) . However, there is mounting evidence that senescent cells accumulate in tissues over time and can promote carcinogenesis in older individuals. As part of the SASP, senescent cells secrete factors with promalignant effects, such as the growth-related oncogene (GRO), and factors that promote degradation and invasion of the basement membrane, such as interleukins (IL-6 and IL-8), vascular endothelial growth factor (VEGF), and matrix metalloproteases (reviewed in Rodier and Campisi, 2011; Coppé et al., 2010) . Together, these lines of evidence indicate that senescence could function as a tumor-suppressive mechanism in young individuals and a tumor-promoting mechanism in older individuals.
Besides cancer, cellular senescence may also contribute to other age-related diseases. For example, overexpression of p53 in mice triggered the accumulation of senescent cells in vivo, linked to the premature appearance of age-associated changes, including loss of fertility and subcutaneous fat, osteoporosis, sarcopenia, thinning of the skin, and reduced hair growth (Tyner et al., 2002; Maier et al., 2004) . In another example, a mouse model of a premature aging 
